These cells have demonstrated activity in preclinical models of melanoma and breast cancer, including CD1d-targeted and MUC1-directed CAR-NKTs, which reduced tumour growth and enhanced survival [37, 170, 174, 316]. Here, CD1D is linked to neoplasm.